CSRxP LAUNCHES ADVERTISING CAMPAIGN HIGHLIGHTING BIG PHARMA’S EGREGIOUS PRACTICES THAT ARE ROOT CAUSE OF HIGH PRESCRIPTION DRUG PRICES, HEALTH CARE INFLATION
Campaign Introduces “Phil the Pill” as New Character Personifying How Big Pharma Tries to Disguise the Truth
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) announced the launch of a new advertising campaign on Thursday, highlighting how Big Pharma’s patent abuse tactics and egregious pricing practices are the root cause of high prescription drug costs, and a major driver of health care inflation, in America. The new ad introduces “Phil the Pill,” a new character who highlights the many ways Big Pharma tries to “disguise the truth” of brand name manufacturers’ role in making prescription drugs and health care unaffordable for too many Americans — by pointing fingers at others and relying on debunked innovation rhetoric.
“Big Pharma loves to point fingers at others and rehash debunked arguments on innovation in order to avoid accountability for brand name manufacturers, oppose solutions that would lower drug prices for American patients and maintain the pharmaceutical industry’s business-as-usual approach to price-gouging,” said CSRxP executive director Lauren Aronson. “CSRxP’s new campaign showcases the absurdity of Big Pharma’s blame game, underscoring that brand name drug companies’ egregious pricing practices and anti-competitive tactics are the root cause of high prescription drug prices and a major driver of health care inflation in America. Delivering more affordable health care for the American people must mean holding Big Pharma accountable to lower prescription drug prices.”
Watch CSRxP’s new ad “Master of Disguise” HERE.
The campaign follows the release of a recent CSRxP analysis revealing that the pharmaceutical industry continues to post profit margins 10 times higher than other sectors of the prescription drug supply chain. The updated findings confirm that Big Pharma’s egregious pricing and anti-competitive playbook continue to drive blockbuster profits at the expense of patients.
Read more on CSRxP’s new margin analysis HERE.
Read more on bipartisan, market-based solutions to lower drug prices by holding Big Pharma accountable for anti-competitive abuse of the U.S. patent system HERE.
###
